The stock of Bellerophon Therapeutics, Inc. (BLPH) declined slightly in the pre-market following the news of its update on the phase 2 trials of INOpulse. The stock of the company was valued at $2.69 in the pre-market. This is a loss of more than 15.67% from the previously closed value. At the end of the last trading session, the stock closed at $3.19. The volume of the shares traded in the last trading session was around 1.56 million shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Reason for the stock decline
Although the stock closed the last Friday and so did the news that came on Friday but still, the stock of the company declined today in the pre-market. The company on Friday announced in a press release the results of their phase 2 trials for the treatment of pulmonary hypertension related to sarcoidosis from the dose-escalated study of INOpulse.
The study showed that the phase two results of the study give an insight into the clinically meaningful reduction in pulmonary vascular resistance. In the study, 8 subjects showed a decrease after given the dose of INOpulse for the treatment of mean pulmonary arterial pressure and pulmonary vascular resistance or PVR.
When given the 45mcg/kg IBW/hr dose of iNo45 the median drop was around 20%. When it was increased to the highest dose iNO24 mcg/kg IBW/hr the median drop was around 29% in 7 out of 8 patients. The median drop in the mean pulmonary arterial pressure decreased by 6-10% when the patients were given the doses of iNO30 to iNO125.
No serious or adverse effects were witnessed in the trials among the patients. The study showed that the treatment is safe and reliable having no adverse events emerged.
Effect on the stock loss
The stock of the company declined in the pre-market after the press release on Friday. The news itself doesn’t seem to affect the stock of the company. There must be some external reason for the stock of the causing its decline. The reason could be the excessive trade volume of its stock in the market. The volume of the stock trading significantly increased in the last trading session.
Conclusion
The market closed the last Friday and the stock is declining today in the pre-market after the excessive trade volume of its stock. Today will be a crucial day for the stock of the company when the regular trading market opens.
